Year: 2019

Nanologica stärker bolagets kassa genom lån om 4 MSEK

Nanologica AB har upptagit lån om 4 MSEK inom de kreditramar som tecknats med Thomas Eldered. Lånet som upptagits stärker bolagets kassa och ligger inom den kreditram som tecknades med Thomas Eldered i samband med att Nanologica startade storskalig produktion hos kontraktstillverkaren Sterling Pharma Solution i England. Thomas Eldered är Nanologicas största ägare genom bolaget Flerie Invest AB och således närstående till Nanologica. Efter transaktionen kvarstår 10 MSEK inom kreditramen.   För ytterligare information, vänligen

Read more »

Förnyat avtal med jordbruksföretag

Nanologica förnyar avtalet med det jordbruksföretag som under året bedrivit fältstudier baserade på Nanologicas formulering av en aktiv ingrediens i växtskydd. Det förnyade samarbetet syftar till att ytterligare optimera formuleringen, samt formulering av andra aktiva ingredienser. Avtalsvärdet uppgår till cirka 948 TSEK (€ 90 000) fördelat under första halvåret 2020. Nanologica ingick i september 2017 ett samarbetsavtal med ett globalt jordbruksföretag specialiserat på växtskydd, i syfte att förbättra formuleringen av en aktiv ingrediens i växtskydd. Avtalet

Read more »

Renewed agreement with crop protection company

Nanologica has renewed the agreement with the crop protection company that during the year has performed field studies based on Nanologica’s formulation of an active ingredient for crop protection. The purpose of the new agreement is to further optimize this formulation, as well as formulating other active ingredients. The value of the agreement amounts to approx. TSEK 948 (€ 90 000) distributed over the first half of 2020. In September 2017 Nanologica entered into an agreement

Read more »

Nanologica to attend conferences devoted to respiratory drug delivery

Nanologica’s technology platform for drug delivery has developed to include inhalation as administration route. Great interest has been shown in the platform and Nanologica now aims to further discuss the platform with leaders in the field and with potential partners. On Dec 5-6, Nanologica will take part in the inaugural Respiratory Drug Delivery conference in London, UK. The purpose of the conference is to bring together clinical researchers, respiratory drug manufacturers and solution providers to

Read more »

Nanologica acknowledges World Diabetes Day

November 14 marks the date for the World Diabetes Day. For Nanologica, the day is highly relevant as the Company is working with solutions for diabetes related issues in both its business areas. Diabetes is a disease affecting more than 400 million people worldwide, a number that is expected to increase to more than 640 million by 2040. In 2015 diabetes was the cause of 5 million deaths and more than 200 million people are

Read more »

Update from BIO Europe

Nanologica is taking part of BIO Europe in Hamburg, Europe’s largest life science partnering conference. Listen to the update from our CTO Adam Feiler talking about our platform for pulmonary delivery and our Director Drug Development Kia Bengtsson, talking about Nanologica’s clinical development program NIC-001 :

Read more »